Table 2.
Safety of VCM versus that of PCM by questionnaire.
| Any (AEQ 2 or 3) | AEQ 3 | |||||
|---|---|---|---|---|---|---|
| VCM | PCM | p | VCM | PCM | p | |
| Diarrhea | 5.0% | 6.7% | 1 | 0% | 0% | 1 |
| Dysgeusia | 0% | 6.7% | 0.38 | 0% | 6.7% | 0.51 |
| Nausea | 15.0% | 0% | 0.06 | 10.0% | 0% | 0.16 |
| Anorexia | 10.0% | 3.3% | 0.56 | 5.0% | 3.3% | 1 |
| Abdominal pain | 15.0% | 3.3% | 0.29 | 5.0 | 0% | 0.40 |
| Heart burn | 10.0% | 6.7% | 1 | 0% | 3.3% | 1 |
| Hives | 0% | 3.3% | 1 | 0% | 3.3% | 1 |
| Headache | 10.0% | 0% | 0.16 | 5.0% | 0% | 0.40 |
| Abdominal fullness | 30.0% | 3.3% | 0.012 | 15.0% | 0% | 0.06 |
| Belch | 5.0% | 0% | 0.40 | 0% | 0% | 1 |
| Vomiting | 0% | 0% | 1 | 0% | 0% | 1 |
| General malaise | 15.0% | 3.3% | 0.29 | 0% | 3.3% | 1 |
| Others | 5.0% | 3.3% | 1 | 0% | 0% | 1 |
AEQ: adverse effects questionnaire; AEQ 2: moderate; AEQ 3: strong, VCM: vonoprazan/CAM/MNZ 1-week eradication therapy; PCM: PPI (LPZ or ESO)/CAM/MNZ 1-week eradication therapy.